Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 433-437

  Nguyen, Thi Mai Hoang ^a   Daubard, Marina ^a   Le Gall, Catherine ^b   Larger, Magali ^a   Lachaux, Alain ^b   Boulieu, Roselyne ^a  

^a UNIVERSITÉ DE LYON   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

autoimmune hepatitis; pediatric patients; thiopurine metabolites

Indexed keywords

6 METHYL MERCAPTOPURINE NUCLEOTIDE DERIVATIVE; 6 THIOGUANINE NUCLEOTIDE DERIVATIVE; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; UNCLASSIFIED DRUG; 6-METHYLTHIOPURINE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; TIOGUANINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; ASCITES; AUTOIMMUNE HEPATITIS; BONE MARROW TOXICITY; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MONITORING; ENTERITIS; ERYTHROCYTE COUNT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MEGALOCYTOSIS; NEUTROPENIA; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; BLOOD CELL COUNT; DRUG COMBINATION; HEPATITIS, AUTOIMMUNE; LIVER FUNCTION TEST;

6-MERCAPTOPURINE; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BIOTRANSFORMATION; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; MALE; THIOGUANINE;

EID: 77955173250     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dbd712     Document Type: Article

References (21)

1. Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of patients with autoimmune hepatitis. J Hepatol. 2006;45:584-591.
2. Lueth S, Lohse AW. Autoimmune hepatitis. Clin Med. 2006;6:25-28.
3. Muratori P, Granito A, Pappas G, et al. Autoimmune liver disease 2007. Mol Aspects Med. 2008;29:96-102.
4. Rumbo C, Emerick KM, Emre S, et al. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr. 2002;35:391-398.
5. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
6. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
7. Coulthard S, Hogarth L. The thiopurine: an update. Invest New Drugs. 2005;23:523-532.
8. Telm A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease. Clin Pharmacokinet. 2007;46:187-208.
9. Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenter-ological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130: 940-987.
10. Derijks LJJ, Gilissen LPL, Hooymans PM, et al. Thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-729.
11. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmaco-genetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20:1149-1157.
12. Rumbo C., Schneider B, Emre S. Utility of azathioprine metabolite measurement in post-transplant recurrent autoimmune and autoimmune-mediated hepatitis. Pediatr Tranplant. 2004;8:571-575.
13. Wusk B, Kullack-Ublick GA, Rammert C, et al. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2004;16: 1407-1413.
14. Dervieux T, Boulieu R. Identification of 6-methylmercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clin Chem. 1998;44: 2511-2515.
15. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998;44:551-555.
16. Boulieu R, Sauviat M, Dervieux T, et al. Phenotype determination of thiopurine methyltransferase in erythrocytes by HPLC. Clin Chem. 2001; 47:956-958.
17. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
18. Cuffari C, Théorêt Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406.
19. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14: 1009-1014.
20. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyl transferase activity and azathoprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
21. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081-1085.